Pathogens Enzyme-Based Anthrax Therapy Shows Promise in Preclinical TrialsGlobal Biodefense StaffJune 17, 2025
Medical Countermeasures Novel Oral Chitosan-Based Compound Shows Promise for Radiological Emergency ResponseGlobal Biodefense StaffJune 12, 2025
Medical Countermeasures Single-Dose VSV Vaccine Fully Protects Mice Against Crimean-Congo Hemorrhagic FeverGlobal Biodefense StaffJune 5, 2025
Needle-Free Influenza Vaccines: HKUMed Advances New Live-Attenuated Platforms with Cross-Subtype Potential Medical Countermeasures May 9, 2025 …
New Monoclonal Antibodies Offer Hope for Universal Influenza Treatment Medical Countermeasures May 1, 2025 …
Innovative VLP-Based Vaccine Shows Promise Against Avian Influenza Medical Countermeasures April 30, 2025 …
Federal Scientists Use AI to Optimize Antibodies Against Mutations Medical Countermeasures April 7, 2025 …
W.H.O. Partner Program Allocates 238,000 Doses of Mpox Vaccine to Four Countries Medical Countermeasures March 19, 2025 …
Emergent BioSolutions Secures $27 Million in International Orders for Critical Medical Countermeasures Medical Countermeasures March 18, 2025 …
Tecovirimat Shown to Lack Efficacy as Treatment for Clade II Mpox Medical Countermeasures March 12, 2025 …
Bolstering Pandemic Preparedness: HHS Funds Accelerated Development of H5N1 Vaccine Medical Countermeasures January 17, 2025 …
FDA Removes Clinical Hold on Novavax’s Combo COVID-Flu Vaccine Medical Countermeasures November 11, 2024 …
Humanetics Presents BIO 300 Radiation Countermeasure Data at DoD Scientific Meeting Medical Countermeasures October 3, 2024 …
GigaGen Wins BARDA Contract to Develop Biothreat Countermeasures Medical Countermeasures October 3, 2024 …
Acurx Announces Anthrax Susceptibility to ACX-375 Analogues Medical Countermeasures September 26, 2024 …
New Partnerships Boost Decentralized Clinical Trial Capacity for Public Health Emergencies Contracts + Grants August 27, 2024 …
Disappointing Results for Tecovirimat Mpox Trial in the DRC Medical Countermeasures August 15, 2024 …
Lassa Fever Vaccine Study Supports Advancement to Phase I Trial Medical Countermeasures August 14, 2024 …
Thylacine Biotherapeutics Earns Top Honor in Medical Threat Reduction Challenge Medical Countermeasures July 9, 2024 …
